The biosurgery Market will surge at 5.7% CAGR

The market for biosurgery will grow at a healthy 5.7% CAGR, from its estimate value of $15.93 million in 2021 to $26.25 billion by 2030.

The trend of bio-surgery is attracting investments in R&D and providing prospective business prospects. Living cells are increasingly being use to treat wounds because they enable quicker healing and better tissue regeneration, even in the most challenging circumstances. Additionally, bio-base wound care methods have been found to significantly lessen wound scarring when compare to traditional patches and stitches. It is anticipate that more businesses that currently sell traditional wound healing goods will soon expand their product lines to include bio-base wound care items, including patches, scar sealants, and much more. Porcine collagen, bio-base electrospun fibers, blood-derive materials, and other materials are being use to create novel bio-base wound dressing approaches.

Market Dynamics


  • Procedures for tissue adhesion & repair are being revolutionize by new items that are being create. Fibrin sealants are utilize in contemporary wound treatments together with a variety of applicator technologies to stop bleeding while the site is being treat. In order to cure wounds, businesses have create ready-to-use patches that may be apply to both dry and moist locations.
  • Accidents have raise the need for lengthy surgery procedures, which has boost the demand for products that effectively control blood loss. The hemorrhage causes more than 35 percent of pre-hospital fatalities and more than 40% of deaths that occur within 24hrs of the injury, according to the National Trauma Institute. Thus, one of the key drivers driving the biosurgery market is the necessity to minimize blood loss. This result in increasing use of biosurgery goods over conventional products.


The market for biosurgery commands high prices since existing competitors are engage in intense competition. The targeted patient population in growing countries prefers the conventional product throughout surgeries due to the high cost & hospital payment scenario for these goods, which then, in turn, is limiting & restraining the market growth. Owing to the high cost of biosurgery products, emerging nations choose to perform surgeries using traditional methods like sutures and ligature-base treatments.


The adoption of cutting-edge biosurgical products is on the rise in emerging nations. Large patient populations for the target indications (cardiovascular, Gynecological, and orthopaedic illnesses), expanding health awareness, increasing medical tourism, rising healthcare spending, and quickly evolving healthcare infrastructure are characteristics of the markets in emerging nations. In emerging economies, medical procedures are considerably less expensive than in industrialize ones. Government organizations in these regions are also taking steps to assist their particular healthcare systems, which fosters market growth and increases opportunities for biosurgery.

Market Segmentation

The market is bifurcate into:

Based on Surgery

·        General

·        Orthopedic

·        Cardiovascular

·        Neurological

·        Gynecological

·        Reconstructive

·        Thoracic

·        Urological

Based on Origin

·        Synthetic

·        Biological

Based on End-user

·        Clinics

·        Hospitals

·        ASCs

·        Others


North America

· USA/America

· Mexico

· Canadian Provinces

· Rest of N.A.


· Suomi

· Germany

· Hungary

· France

· U.K.

· Netherlands

· Turkey

· Rest of Europe

Asia Pacific

· China

· Japan

· South Korea

· Australia

· India

· Remaining APAC


· Argentina

· Saudi Arabia

· Brazil

· Uruguay

· Rest of L.A.M.E.A.

By surgery, the general surgery segment, which had a strong CAGR of 8.6%, dominate global biosurgery market in 2020. The total growth of this market is being fuel by elements like the acceleration of technological development and the increase popularity of technically sophisticate surgeries in emerging nations. Base on the Estimation of National Surgical Needs of India 2020, 949 procedures are carry out each year, 614 of which are conduct on men and 335 on women.

In 2020, the Hospitals category will hold a sizable market share base on End Users. The segment’s overall expansion is being driven by elements including the exponential growth of hospitals, infrastructural and economic development, particularly in emerging nations, and the growing amount of surgical procedures carry out in hospital operating rooms. According to Stanford Health, around 48 million procedures are carry out annually in hospitals, with cardiac disorders accounting for the largest proportion—nearly 7.3 million—in the United States.

According to regions, North America held the highest market share in 2020. The N.A. region has the highest percentage, which is primarily due to the region’s reimbursement policy initiatives for biosurgery products, growing number of healthcare facilities, extremely develope healthcare system, a growing number of vendors, and growing prevalence of severe trauma, lifestyle disorders, and growing elderly population. More than 46 million persons in the United States are over the age of 65, and by 2050, it is expect to rise to 90 million, base on the rural health information hub. By 2030, it is expect that one in every five Americans will be over 65.

Key Companies

·        Baxter International Inc.

·        Johnson & Johnson

·        Becton, Dickinson & Co.

·        Medtronic Plc

·        Stryker Corp.

·        B. Braun Melsungen AG

·        CSL Ltd.

·        Integra Lifesciences Holdings 

·        Pfizer Inc.

·        Hemostasis L.L.C

·        Zimmer Biomet

·        Cyrolife Inc.